CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 87 enrolled
Drug / intervention
Methylphenidate (MPH)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02695355
NCT02695355Phase 2Completed
CompareCT.gov

Pediatric Attention Deficit Hyperactivity Disorder: Predicting Clinical Response to Stimulant Medication From Single-dose Changes in Event Related Potentials

Ostfold Hospital Trust·interventional·Posted Mar 1, 2016·Updated Mar 1, 2016

In Brief

A Phase 2 clinical trial evaluating Methylphenidate (MPH) for Attention Deficit Hyperactivity Disorder. Completed, enrolled 87 participants across 1 site.

Detailed Summary

The purpose of this study was to see if the clinical outcome of stimulant medication (methylphenidate) in pediatric Attention Deficit Hyperactivity Disorder can be predicted on the bases of changes in Event Related Potentials (ERPs) induced by a single dose of stimulant medication. (ERPs are extracted from electroencephalographic (EEG) registrations during the performance of an attention task).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit Hyperactivity Disorder
CountriesNorway
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 1, 2016
Enrollment StartOct 1, 2006
Primary CompletionJan 1, 2013
Study CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 10.3 years ago

Interventions

Methylphenidate (MPH)drug

Test 1: No medication. Registration of ERPs and behavioral data during an attention task. Test 2: Test repeated on a single dose of MPH. Outcome measure: Classification as responders or non-responders after a four weeks medication trial, based on rating scales from parents and Teachers.